Skip to main content

Table 3 Key studies of TNF-blocker therapy in ankylosing spondylitis

From: Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future

Outcomes reported
Therapy Published study Primary outcome Radiologic outcome Follow-up BASDAI BASFI BASMI QoL EMS Fatigue CRP/ ESR
Infliximab Braun and colleagues [96100] 50% improvement in BASDAI at week 12 mSASSS 5 years x x x x x   x
Infliximab Marzo-Ortega and colleagues [101] Change in BASDAI at weeks 4, 10, 30 MRI inflammatory lesions 30 weeks x x   x x   x
Infliximab van der Heijde and colleagues [83, 102] ASAS 20 at week 24 mSASSS 8 years x x x x x x x
Etanercept Davis and colleagues [103105], van der Heijde and colleagues [84] ASAS 20 at week 12 mSASSS 16 years x x x   x   x
Etanercept Calin and colleagues [106], Dijkmans and colleagues [107] ASAS 20 at week 12 mSASSS 8 years x x x   x   x
Adalimumab van der Heijde and colleagues [108] ASAS 20 at week 12 NA 24 weeks x x x x x   x
Golimumab Inman and colleagues [109] ASAS 20 at week 14 NA 24 weeks x x x x x   x
  1. ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate; EMS, early morning stiffness; MRI, magnetic resonance imaging; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NA, not applicable; QoL, quality of life.